Loading, Please Wait...
EDEN PRAIRIE, Minn., April 03, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the submission of a method of use application to the United States Patent and Trademark Administration for pediatric use of its Aquadex Flex Flow System.
Illustrative claims in the application include customizable circuit volume for optimizing pediatric patient hemodynamics and a mechanism to ensure the safety of pediatric patients.
“We remain dedicated to the innovation of our technology and to optimizing the application of our Aquadex FlexFlow system, a safe, effective and clinically-proven solution to manage fluid overload,” said John Erb, chairman and CEO of CHF Solutions. “As we seek FDA clearance to modify the label of Aquadex to include pediatric patients, we intend to ensure that we have intellectual property protection to support the expanded use when the expected clearance is received.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, that this patent will provide sufficient intellectual property protection and the modification to the label of Aquadex FlexFlow system for pediatric use will receive clearance from the FDA. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
JQA Partners, Inc.